Total Survivin and acetylated Survivin correlate with distinct molecular subtypes of breast cancer

Human Pathology

Volumn 43, Issue 6, 2012, Pages 865-873

  Yakirevich, Evgeny ^a   Samkari, Ayman ^a   Holloway, Michael P ^a   Lu, Shaolei ^a   Singh, Kamaljeet ^a   Yu, Jovian ^a   Fenton, Mary Anne ^a   Altura, Rachel A ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Acetylation; Basal breast cancer; Breast cancer; Survivin; Triple negative breast cancer

Indexed keywords

SURVIVIN;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ACETYLATION; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861183393     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.07.014     Document Type: Article

References (39)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. R.W. Carlson, D.C. Allred, and B.O. Anderson Invasive breast cancer J Natl Compr Canc Netw 9 2011 136 222
3. C.M. Perou, T. Sorlie, and M.B. Eisen Molecular portraits of human breast tumours Nature 406 2000 747 752
4. T. Sorlie, C.M. Perou, and R. Tibshirani Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 2001 10869 10874 (Pubitemid 32878711)
5. E.A. Rakha, and I.O. Ellis Triple-negative/basal-like breast cancer: review Pathology 41 2009 40 47
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
7. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70 (Pubitemid 30046295)
8. T. Dohi, K. Okada, and F. Xia An IAP-IAP complex inhibits apoptosis J Biol Chem 279 2004 34087 34090 (Pubitemid 39318028)
9. A.D. Schimmer Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice Cancer Res 64 2004 7183 7190 (Pubitemid 39372048)
10. S. Yamashita, Y. Masuda, and T. Kurizaki Survivin expression predicts early recurrence in early-stage breast cancer Anticancer Res 27 2007 2803 2808 (Pubitemid 47228001)
11. R. Moriai, N. Tsuji, M. Moriai, D. Kobayashi, and N. Watanabe Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells Breast Cancer Res Treat 117 2009 261 271
12. A.R. Hinnis, J.C. Luckett, and R.A. Walker Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients Br J Cancer 96 2007 639 645
13. A. Nassar, D. Lawson, G. Cotsonis, and C. Cohen Survivin and caspase-3 expression in breast cancer: correlation with prognostic parameters, proliferation, angiogenesis, and outcome Appl Immunohistochem Mol Morphol 16 2008 113 120
14. P.N. Span, V.C. Tjan-Heijnen, P. Manders, D. van Tienoven, J. Lehr, and F.C. Sweep High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer Breast Cancer Res Treat 98 2006 223 230 (Pubitemid 44050773)
15. D.C. Altieri Survivin, cancer networks and pathway-directed drug discovery Nat Rev Cancer 8 2008 61 70
16. A.C. Mita, M.M. Mita, S.T. Nawrocki, and F.J. Giles Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics Clin Cancer Res 14 2008 5000 5005
17. P. Fortugno, N.R. Wall, and A. Giodini Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function J Cell Sci 115 2002 575 585 (Pubitemid 34182984)
18. S.M. Lens, G. Vader, and R.H. Medema The case for Survivin as mitotic regulator Curr Opin Cell Biol 18 2006 616 622 (Pubitemid 44711886)
19. S.M. Kennedy, L. O'Driscoll, and R. Purcell Prognostic importance of survivin in breast cancer Br J Cancer 88 2003 1077 1083 (Pubitemid 36560779)
20. E. Rexhepaj, K. Jirstrom, and D.P. O'Connor Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer BMC Cancer 10 2010 639
21. D.J. Brennan, E. Rexhepaj, and S.L. O'Brien Altered cytoplasmic-to- nuclear ratio of survivin is a prognostic indicator in breast cancer Clin Cancer Res 14 2008 2681 2689
22. G.G. Dogu, M. Ozkan, F. Ozturk, M. Dikilitas, O. Er, and A. Ozturk Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin Med Oncol 27 2010 34 39
23. K. Mujoo, M. Watanabe, J. Nakamura, A.R. Khokhar, and Z.H. Siddik Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents J Cancer Res Clin Oncol 129 2003 709 718 (Pubitemid 38002302)
24. C. Page, M. Huang, and X. Jin Elevated phosphorylation of AKT and Stat3 in prostate, breast, and cervical cancer cells Int J Oncol 17 2000 23 28
25. H. Wang, M.P. Holloway, and L. Ma Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity J Biol Chem 285 2010 36129 36137
26. C.W. Elston, and I.O. Ellis Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow- up Histopathology 19 1991 403 410
27. T.O. Nielsen, F.D. Hsu, and K. Jensen Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 2004 5367 5374 (Pubitemid 39100473)
28. S.B. Edge, D.R. Byrd, and C.C. Compton AJCC cancer staging manual 2010 347 376
29. A.C. Wolff, M.E. Hammond, and J.N. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 2007 18 43 (Pubitemid 46174133)
30. M. Lechpammer, M.B. Resnick, and E. Sabo The diagnostic and prognostic utility of claudin expression in renal cell neoplasms Mod Pathol 21 2008 1320 1329
31. S. Pruthi, K.R. Brandt, and A.C. Degnim A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis Mayo Clin Proc 82 2007 999 1012 (Pubitemid 47206376)
32. R.H. Alvarez, V. Valero, and G.N. Hortobagyi Emerging targeted therapies for breast cancer J Clin Oncol 28 2010 3366 3379
33. W.D. Foulkes, I.E. Smith, and J.S. Reis-Filho Triple-negative breast cancer N Engl J Med 363 2010 1938 1948
34. M. Adamkov, E. Halasova, and K. Kajo Survivin: a promising biomarker in breast carcinoma Neoplasma 57 2010 572 577
35. B.M. Ryan, G.E. Konecny, and S. Kahlert Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1 Ann Oncol 17 2006 597 604
36. D.M. Sohn, S.Y. Kim, and M.J. Baek Expression of survivin and clinical correlation in patients with breast cancer Biomed Pharmacother 60 2006 289 292 (Pubitemid 44223940)
37. M. Tanioka, H. Nokihara, and N. Yamamoto Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors Cancer Chemother Pharmacol 68 2011 505 511
38. I. Honma, H. Kitamura, and T. Torigoe Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer Cancer Immunol Immunother 58 2009 1801 1807
39. T. Tsuruma, F. Hata, and T. Torigoe Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer J Transl Med 2 2004 19